12,372 trials
Iron Deficiency Anemia
Primary: Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8 — 176; 175 Participants
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
Amnestic Mild Cognitive Impairment · Alzheimer's Disease
Primary: Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12) — 3.893; 3.867; 7.091; 6.164 Modeled change score…
Asthma
Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800
Constipation - Functional
Primary: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 47 Participants
Graft-versus-host Disease (GVHD)
Primary: Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index — 74.0; 66.4 Percentage of Participants — p=0.0782
Type2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at 24 Weeks (Part 1) — 8.23; 8.10; 8.07; 8.38 Percentage of glycosylated hemoglobin
Migraine Disorders
Primary: Change From Baseline in Monthly Migraine Days (Weeks 1-12) — -4.3; -3.9; -4.1; -3.1 Migraine Days — p=0.0001
Cystic Fibrosis
Primary: Absolute Change From Baseline in Percent-predicted Forced Expiratory Volume in One Second (ppFEV1) at Week 48 — -1.396; -1.992 Percentage of predicted FEV1 — p=0.5336
Psoriasis
Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 — 7.8; 92.3; 88.9 percentage of participants…
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: Change From Baseline UDI Total Score — -138.8; -142.7; -137; -147.4 units on a scale
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264
Influenza
Primary: Number of Subjects Reporting at Least One A/California Influenza Event — 3; 7; 13 Participants
Down Syndrome
Primary: GMDS (Griffiths Mental Development Scale) — 51.96; 51.27; 51.66; 51.67 developpement quotient
Psoriatic Arthritis
Primary: Number of Participants Achieving American College of Rheumatology 20 (ACR20) Response Criteria — 29; 51; 54; 15 Participants — p=0.0200